Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P623 Cumulative incidence of infliximab use after a first flare of acute severe colitis

ECCO'20 Vienna

Year: 2020
Authors:

M. GHRIBI, G. Mohamed, S. Bizid, B. Ben Sliman, K. Boughoula, H. Ben Abdallah, R. Bouali, M.N. Abdelli

Medical University of Tunis, Gastroenterology-Military Hospital-Tunis, Tunis, Tunisia

P624 Maintenance of remission after treatment with Exclusive Enteral Nutrition and Azathioprine in paediatric patients with Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

G. Pujol Muncunill, A.I. Pascual-Pérez, P. Dominguez-Sánchez, S. Feo-Ortega, M. Suárez-Galvis, V. Vila-Miravet, F.J. Martin de Carpi

Hospital Sant Joan de Déu, Unit for the Comprehensive Care of Pediatric Inflammatory Bowel Disease. Department of Pediatric Gastroenterology- Hepatology and Nutrition, Esplugues de Llobregat, Spain

P625 Kinetics and outcomes of transmural healing in patients with Crohn’s disease treated with anti-TNF therapy

ECCO'20 Vienna

Year: 2020
Authors:

C. Pastaud1, C. Hordonneau2, C. Lambert3, J. Vignette1, B. Pereira3, A. Buisson1

1CHU Estaing, Department of Digestive and Hepatobiliary Medicine- Department of Gastroenterology, Clermont-Ferrand, France, 2CHU Estaing, Radiology Department, Clermont-Ferrand, France, 3CHU, Biostatistics Unit, Clermont-Ferrand, France

P626 Patients with IBD seek extra supportive care: insights from Israeli social media networks

ECCO'20 Vienna

Year: 2020
Authors:

G. SHARVIT1, I. Goren1,2, L. Godny1,2, K. Yadgar2, S. Elial Fatal2, R. Barkan2, D. Turner3, I. Dotan1,2, H. Yanai1,2

1Tel-Aviv University, Sackler Faculty of Medicine, Tel Aviv-Jaffa, Israel, 2Rabin Medical Center, IBD Center- Division of Gastroenterology, Petah-Tikva, Israel, 3Shaare Zedek Medical Center- The Hebrew University of Jerusalem, The Juliet Keidan Institute of Pediatric Gastroenterology and Nutrition, Jerusalem, Israel

P627 Acute severe ulcerative colitis in pregnancy: A retrospective cohort study

ECCO'20 Vienna

Year: 2020
Authors:

J. Ollech1, I. Avni-Biron2, S. Dalal1, L. Glick1, S. Schafer1, J. Pekow1, R. Cohen1, D. Rubin1, A. Sakuraba1

1University of Chicago Medicine, Gastroenterology, Chicago, USA, 2Rabin Medical Center, Gastroenterology, Petach-Tikva, Israel

P628 Histological remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission

ECCO'20 Vienna

Year: 2020
Authors:

N. Narula1, A.A. Alshahrani1, M. Fadida1, M. Al-Saedi1, J.K. Marshall1, D.T. Rubin2, B. Christensen3

1McMaster University, Department of Gastroenterology, Hamilton, Canada, 2University of Chicago, Gastroenterology, Chicago, USA, 3The Royal Melbourne Hospital, Gastroenterology, Melbourne, Australia

P629 Long-term effectiveness and safety of ustekinumab (UST) in patients with active Crohn’s disease (CD) in real life: Interim analysis of the SUSTAIN study

ECCO'20 Vienna

Year: 2020
Authors:

M. Chaparro1, S. Sulleiro2, I. Bastón-Rey3, C. Rodríguez4, I. García-Tercero5, P. Ramírez6, S. García-López7, M. Rojas-Feria8, A. Gutiérrez9, J.M. Huguet Malavés10, M.F. García-Sepulcre11, B. Sicilia12, F. Bermejo13, F. Rodríguez-Moranta14, F. Argüelles15, I. Marín16, E. Leo17, M. Arroyo18, M.J. García19, J.M. Vázquez20, D. Ginard21, J. Martínez Cadilla22, C. Rubín de Célix1, A. García-Herola23, A. Hernández-Camba24, M.D. Martín-Arranz25, S. Riestra26, P. Varela27, B. Velayos28, D. Busquets29, C. Dueñas30, E. Fernández-Salgado31, P. Martínez-Montiel32, M.T. Diz-Lois33, Y. González-Lama34, A. Muñagorri35, M. Navarro-Llavat36, C. Guisado2, M. Barreiro-de Acosta3, J.P. Gisbert1, on behalf of SUSTAIN Study Group

1Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa IIS-IP- Universidad Autónoma de Madrid, and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Gastroenterology Unit, Madrid, Spain, 2Janssen, Medical Department, Madrid, Spain, 3Complejo Hospitalario Universitario de Santiago, Gastroenterology Unit, Santiago de Compostela, Spain, 4Complejo Hospitalario de Navarra, Gastroenterology Unit, Pamplona, Spain, 5Hospital Universitario Santa Lucía, Gastroenterology Unit, Cartagena, Spain, 6Hospital Universitario Áraba, Gastroenterology Unit, Vitoria, Spain, 7Hospital Universitario Miguel Servet, Gastroenterology Unit, Zaragoza, Spain, 8Hospital Universitario Nuestra Señora de Valme, Gastroenterology Unit, Sevilla, Spain, 9Hospital General Universitario de Alicante and CIBERehd, Gastroenterology Unit, Alicante, Spain, 10Hospital General Universitario de Valencia, Gastroenterology Unit, Valencia, Spain, 11Hospital General Universitario de Elche, Gastroenterology Unit, Elche, Spain, 12Complejo Asistencial Universitario de Burgos, Gastroenterology Unit, Burgos, Spain, 13Hospital Universitario de Fuenlabrada- Instituto de Investigación de Hospital La Paz IdiPaz- Madrid, Gastroenterolgoy Unit, Madrid, Spain, 14Hospital Universitario de Bellvitge, Gastroenterology Unit, Barcelona, Spain, 15Hospital Universitario Virgen Macarena, Gastroenterology Unit, Sevilla, Spain, 16Hospital Universitario Gregorio Marañón- IiSGM and CIBERehd, Gastroenterology Unit, Madrid, Spain, 17Hospital Universitario Virgen del Rocío, Gastroenterology Unit, Sevilla, Spain, 18Hospital Clínico Universitario, Lozano Blesa and CIBERehd- IIS Aragón, Gastroenterology Unit, Zaragoza, Spain, 19Hospital Universitario Marqués de Valdecilla, Gastroenterology Unit, Santander, Spain, 20Hospital Juan Ramón Jiménez, Gastroenterology Unit, Huelva, Spain, 21Hospital Universitario Son Espases, Gastroenterology Unit, Palma de Mallorca, Spain, 22Hospital Alvaro Cunqueiro, Gastroenterology Unit, Vigo, Spain, 23Hospital Marina Baixa, Gastroenterology Unit, Alicante, Spain, 24Hospital Universitario Nuestra Señora de la Candelaria, Gastroenterology Unit, Santa Cruz de Tenerife, Spain, 25Hospital Universitario La Paz-Innate Immunity Group- IdiPAZ Institute for Health Research, Gastroenterology Unit, Madrid, Spain, 26Hospital Universitario Central de Asturias, Gastroenterology Unit, Oviedo, Spain, 27Hospital Universitario de Cabueñes, Gastroenterology Unit, Gijón, Spain, 28Gastroenterology Unit, Hospital Clínico Universitario de Valladolid, Valladolid, Spain, 29Hospital Universitari de Girona Dr. Josep Trueta, Gastroenterology Unit., Girona, Spain, 30Hospital San Pedro de Alcántara, Gastroenterology Unit, Cáceres, Spain, 31Complexo Hospitalario Universitario de Pontevedra, Gastroenterology Unit, Pontevedra, Spain, 32Hospital Universitario Doce de Octubre, Gastroenterology Unit, Madrid, Spain, 33Complejo Hospitalario Universitario de A Coruña, Gastroenterology Unit, A Coruña, Spain, 34Hospital Universitario Puerta de Hierro Majadahonda, Gastroenterology Unit, Madrid, Spain, 35Hospital Universitario Donostia, Gastroenterology Unit, San Sebastián, Spain, 36Hospital de Sant Joan Despí Moisès Broggi, Gastroenterology Unit, Barcelona, Spain

P630 Complete endoscopic remission is not only associated with higher mucosal concentrations of 5-aminosalicylic acid but also with N-acetyl-5-aminosalicylic acid in patients with ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

T. Fukuda1, M. Naganuma1, K. Takabayashi2, Y. Hagihara1, S. Tanemoto1, E. Nomura1, Y. Yoshimatsu1, S. Sugimoto1, K. Nanki1, S. Mizuno1, Y. Mikami1, K. Fukuhara3, T. Suzino1, M. Mutaguchi2, N. Inoue3, H. Ogata2, Y. Iwao3, T. Kanai1

1Keio University School of Medicine, Division of Gastroenterology and Hepatology- Department of Internal Medicine, Tokyo, Japan, 2Keio University School of Medicine, Center for Diagnostic and Therapeutic Endoscopy-, Tokyo, Japan, 3Keio University School of Medicine, Center for Preventive Medicine- Keio University School of Medicine-, Tokyo, Japan

P631 Predictors of vedolizumab treatment persistence in bio-naïve ulcerative colitis patients

ECCO'20 Vienna

Year: 2020
Authors:

T.E. Ritter1, H.E. Sarles2, S.A. Mehta3, L.J. Van Anglen3

1GI Alliance, Clinical Research and Education, Southlake, TX, USA, 2Digestive Health Associates of Texas, DHAT Research Institute, Richardson, TX, USA, 3Healix, Pharmacy and Clinical Research, Sugar Land, TX, USA

P632 Vedolizumab dose escalation in patients with inflammatory bowel disease experiencing loss of response: A systematic review and meta-analysis of real-world evidence

ECCO'20 Vienna

Year: 2020
Authors:

D. Varghese1, D. Patel2, S. Martin2, M. Luo3, L. Ursos4, R. Lirio5, S. Wang3

1Pharmerit International, Real-World Evidence and Data Analytics, Bethesda, USA, 2Pharmerit International, Strategic Market Access, Bethesda, USA, 3Takeda Pharmaceuticals International, Global Outcomes Research and Epidemiology, Cambridge, USA, 4Takeda Pharmaceuticals USA Inc., US Medical, Deerfield, USA, 5Takeda Development Center Americas, Clinical Science, Cambridge, USA

P633 Sustained reduction of IL-23-related cytokines IL-17A and IL-22 in a phase 2 study of mirikizumab in the treatment of patients with moderately-to-severely active ulcerative colitis through week 52

ECCO'20 Vienna

Year: 2020
Authors:

G.R. D’Haens1, B.E. Sands2, T. Kobayashi3, J.L. Tuttle4, J. Schmitz5, R. Higgs5, S. Ho5, S.E. Sissons5, W.J. Sandborn6

1Amsterdam University Medical Centers, Inflammatory Bowel Disease Centre, Amsterdam, The Netherlands, 2Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York NY, USA, 3Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan, 4Eli Lilly and Company, Lilly Biotechnology Center, San Diego CA, USA, 5Eli Lilly and Company, Lilly Biomedicines, Indianapolis IN, USA, 6University of California San Diego, Division of Gastroenterology, La Jolla CA, USA, Background

P634 Predictors of response and course in patients with inflammatory bowel disease treated with biological therapy: The Danish IBD-Biobank project

ECCO'20 Vienna

Year: 2020
Authors:

M. Zhao1, F. Bendtsen1, A.M. Petersen1,2, L. Larsen3, T. Jess3,4, A. Dige5, C. Hvas5, J. Seidelin6, J. Burisch1

1Hvidovre University Hospital, Gastro Unit- Medical Division, Hvidovre, Denmark, 2Hvidovre University Hospital, Dept. of Clinical Microbiology, Hvidovre, Denmark, 3Aalborg University Hospital, Department of Gastroenterology and Hepatology, Aalborg, Denmark, 4The State Serum Institute, Departmentof Epidemiology Research, Copenhagen, Denmark, 5Aarhus University Hospital, Department of Hepatology and Gastroenterology, Aarhus, Denmark, 6Herlev University Hospital, Gastro Unit- Medical Division, Herlev, Denmark

P635 Superior outcomes with early biologic-combination treatment in Crohn’s Disease: Data from an international inception cohort

ECCO'20 Vienna

Year: 2020
Authors:

M. Matheeuwsen1, K. Vermeijden1, P. Bossuyt2, L. Pouillon2, F. Baert3, N. de Boer4, M. Duijvestein4, M. Löwenberg1, C. Ponsioen1, W. Bemelman5, G. D’Haens1, K. Gecse1

1Amsterdam UMC- Academic Medical Center, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands, 2Imelda GI Clinical Research Center, Department of Gastroenterology, Bonheiden, Belgium, 3AZ Delta hospital, Department of Gastroenterology, Roeselare, Belgium, 4Amsterdam UMC- VU University Medical Center- AGandM Research Institute, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands, 5Amsterdam UMC- Academic Medical Center, Department of Surgery, Amsterdam, The Netherlands

P636 Changes in peripheral helper T-cell was associated with sustained response to a 12-week EEN therapy in active Crohn’s disease: A pilot study

ECCO'20 Vienna

Year: 2020
Authors:

K. Guo1,2, W. Gong3, T. Zheng4, W. Li1, M. Fang4, H. Xie4, G. Wang4, G. Gu4

1Department of General Surgery, Medical School of Nanjing University, Nanjing, China, 2The First Affiliated Hospital of USTC, Department of General Surgery, Hefei, China, 3Department of General Surgery, School of Medicine, Southeast University, Nanjing, China, 4Department of General Surgery, Jinling Hospital, Nanjing Medical University, Nanjing, China

P637 PERFUSE: A french non-interventional cohort study of infliximab-naive and transitioned patients receiving infliximab biosimilar SB2; An interim analysis

ECCO'20 Vienna

Year: 2020
Authors:

Y. Bouhnik1, B. Fautrel2, G. Desjeux3, U. Freudensprung4, A. Brigui5, J. Addison6

1Beaujon Hospital, Department of Gastroenterology- AP-HP- Paris Diderot University, Clichy, France, 2Pitié-Salpêtrière Hospital, Department of Rheumatology- AP-HP- Sorbonne University- UPMC university, Paris, France, 3E-health Services Sanoïa, Digital CRO, Gémenos, France, 4Biogen International GmbH, n/a, Zug, Switzerland, 5Biogen France SAS, n/a, Paris, France, 6Biogen UK, n/a, Maidenhead, UK

P638 Stenotic Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

W. El Ouardi, L. Nawal, B. Imane, B. Camelia, B. Mohamed, A. Fatima Zahra

Ibn Sina University Hospital Mohamed V University- Souissi- Rabat, Medicine C, Rabat, Morocco

P639 Outcomes of a clinical psychology intervention in a UK IBD service

ECCO'20 Vienna

Year: 2020
Authors:

F. Eldridge DClin Psyc, K. Strongili, M. Parkes, T. Raine

Addenbrooke’s Hospital, Dept of Gastroenterology, Cambridge, UK

P640 Moderate to severe endoscopic inflammation is frequent after clinical remission in pediatric ulcerative colitis: A cause for disease extension and relapse?

ECCO'20 Vienna

Year: 2020
Authors:

C. Sarbagili Shabat1,2, D. Weiner1, J. Wardi3, L. Abramas1, M. Yaakov1, A. Levine1,2

1The E. Wolfson Medical Center, Pediatric and Gastroenterology and nutrition unit, Holon, Israel, 2Tel-Aviv University, The Sackler Faculty of Medicine, Tel-Aviv, Israel, 3The E. Wolfson Medical Center, Gastroenterology, Holon, Israel

P641 An increased baseline mucosal TNF burden linked to adalimumab non-response: opportunities for therapeutic drug monitoring

ECCO'20 Vienna

Year: 2020
Authors:

B. Verstockt1, J. Stylli2, P. Rahimian2, A. Rajulapati2, K. Ehring2, D. Thomas3, J. Sabino1, M. Ferrante1, S. Singh2, S. Vermeire1

1IBD Leuven, 1University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 2Progenity Inc., Progenity Inc., San Diego California, USA, 3KU Leuven, Laboratory for Therapeutic and Diagnostic Antibodies- Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium

P642 Serum adalimumab levels measured between days 9 and 13 from drug injection can be interpreted clinically in a similar way to trough levels in patients with inflammatory bowel disease

ECCO'20 Vienna

Year: 2020
Authors:

J. Guardiola Capón1, K. Serra1, L. Rodríguez-Alonso1, E. Santacana2, N. Padullés2, A. Ruiz-Cerulla1, C. Arajol1, B. Camps1, G. Surís1, E. Sanchez1, F. Rodríguez-Moranta1

1Hospital Universitari de Bellvitge, Gastroenterology, Barcelona, Spain, 2Hospital Universitari de Bellvitge, Pharmacy, Barcelona, Spain